Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 20, 2026, 7:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,111 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Dyslipidemias Clear all
Completed Phase 4 Interventional

Colesevelam Treatment for Impaired Fasting Glucose During Niacin Therapy

NCT01239004
View directory record Official record
Conditions
Dyslipidemia, Hyperlipidemia, Hyperglycemia
Interventions
Placebo, Colesevelam
Drug
Lead sponsor
Radiant Research
Other
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
4
States / cities
Chicago, Illinois • Kansas City, Kansas • Minneapolis, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2012 · Synced Jul 20, 2026, 7:34 PM EDT
Withdrawn Not applicable Interventional

Cross-over Pilot Study of Blood Cholesterol Response to Dietary Saturated Fat in Patients With Autosomal Dominant Hypercholesterolemia

NCT03756779
View directory record Official record
Conditions
Familial Hypercholesterolemia
Interventions
Dietary intervention
Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 27, 2018 · Synced Jul 20, 2026, 7:34 PM EDT
Completed Phase 2 Interventional Results available

A Study of LY3561774 in Participants With Mixed Dyslipidemia

NCT05256654
View directory record Official record
Conditions
Dyslipidemias, Lipid Metabolism Disorders, Metabolic Diseases, Hyperlipoproteinemia
Interventions
LY3561774, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
6
States / cities
Waterbury, Connecticut • Oxon Hill, Maryland • Fall River, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2025 · Synced Jul 20, 2026, 7:34 PM EDT
Completed Not applicable Interventional

Study of Medical Assistant Health Coaching in Primary Care for Patients With Chronic Conditions

NCT01220336
View directory record Official record
Conditions
Diabetes, Hypertension, Hyperlipidemia
Interventions
Health coaching by medical assistants in primary care
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 75 Years
Enrollment
441 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
2
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 20, 2014 · Synced Jul 20, 2026, 7:34 PM EDT
Completed Not applicable Interventional

Chronic Effects of Freeze-Dried Strawberry Beverage on Cardiovascular Risk Factors

NCT01883401
View directory record Official record
Conditions
Dyslipidemia, Obesity
Interventions
Freeze-dried strawberries, Dietary fiber
Dietary Supplement
Lead sponsor
Oklahoma State University
Other
Eligibility
19 Years to 72 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Stillwater, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jun 20, 2013 · Synced Jul 20, 2026, 7:34 PM EDT
Completed Phase 3 Interventional Results available

Effects of Colesevelam HCl, Rosiglitazone, Sitagliptin on Control of Blood Glucose and Lipids in Type 2 Diabetes Patients Whose Blood Glucose Isn't Completely Controlled With Metformin

NCT00484419
View directory record Official record
Conditions
Type 2 Diabetes, Hyperlipidemia
Interventions
Colesevelam HCl, rosiglitazone maleate, sitagliptin phosphate
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 80 Years
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
20
States / cities
La Mesa, California • Los Angeles, California • Los Gatos, California + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2016 · Synced Jul 20, 2026, 7:34 PM EDT
Completed Phase 2 Interventional

Study of Oral MD-0727 Administered to Patients With Primary Hypercholesterolemia

NCT00404001
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
MD-0727
Drug
Lead sponsor
Ironwood Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
20
States / cities
Birmingham, Alabama • Los Angeles, California • Walnut Creek, California + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2007 · Synced Jul 20, 2026, 7:34 PM EDT
Terminated Phase 2 Interventional Results available

A Pharmacodynamic Study to Evaluate the Effect of a Fixed Dose Combination Pill on Low Density Lipoprotein (LDL) Cholesterol

NCT01004705
View directory record Official record
Conditions
Elevated LDL Cholesterol
Interventions
Cardiovascular fixed dose combination pill (acetylsalicylic acid, simvastatin and ramipril),, Simvastatin
Drug
Lead sponsor
Ferrer Internacional S.A.
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 30, 2012 · Synced Jul 20, 2026, 7:34 PM EDT
Completed Phase 3 Interventional

A Phase 3 STudy of CaPRe in LOwering Very hiGh TriglYcerides (TRILOGY 2)

NCT03361501
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
CaPre, Placebo
Drug
Lead sponsor
Grace Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
278 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
53
States / cities
Birmingham, Alabama • Childersburg, Alabama • Encino, California + 44 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2020 · Synced Jul 20, 2026, 7:34 PM EDT
Completed Phase 2 Interventional

Evaluation of ETC-1002, Ezetimibe, and the Combination in Hypercholesterolemic Patients

NCT01941836
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
ETC-1002, Ezetimibe
Drug
Lead sponsor
Esperion Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
349 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
68
States / cities
Birmingham, Alabama • Muscle Shoals, Alabama • Chandler, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2019 · Synced Jul 20, 2026, 7:34 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Gene Therapy Study for Homozygous Familial Hypercholesterolemia (HoFH)

NCT02651675
View directory record Official record
Conditions
Homozygous Familial Hypercholesterolemia (HoFH)
Interventions
AAV directed hLDLR gene therapy
Genetic
Lead sponsor
REGENXBIO Inc.
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
5
States / cities
Boca Raton, Florida • Kansas City, Kansas • Portland, Oregon + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2023 · Synced Jul 20, 2026, 7:34 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Peru Longitudinal Study

NCT03742219
View directory record Official record
Conditions
Cardiovascular Diseases, Diabetes Mellitus, Hypertension, Dyslipidemias, Overweight and Obesity
Interventions
Lifestyle Modification
Behavioral
Lead sponsor
Ohio University
Other
Eligibility
12 Years and older
Enrollment
861 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Athens, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 14, 2021 · Synced Jul 20, 2026, 7:34 PM EDT
Terminated Not applicable Interventional Results available

Effect of a Fibrate and a Statin on Endothelial Dysfunction

NCT00491400
View directory record Official record
Conditions
Diabetes Mellitus, Metabolic Syndrome
Interventions
Fenofibrate, Atorvastatin
Drug
Lead sponsor
Boston University
Other
Eligibility
30 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 23, 2012 · Synced Jul 20, 2026, 7:34 PM EDT
Completed Not applicable Interventional Results available

P20 Extending Sleep to Reverse Metabolic Syndrome

NCT03596983
View directory record Official record
Conditions
Metabolic Syndrome
Interventions
Sleep Intervention, Week 2 Intervention
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
35 Years to 60 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 18, 2024 · Synced Jul 20, 2026, 7:34 PM EDT
Completed Phase 3 Interventional Results available

Changes in Lipids and Safety of Raltegravir in HIV+ Patients With Hyperlipidemia While on Current Standard Therapy

NCT00887653
View directory record Official record
Conditions
HIV, Hyperlipidemia, Hypertriglyceridemia, HIV Infections
Interventions
raltegravir
Drug
Lead sponsor
The Miriam Hospital
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
2
States / cities
Boston, Massachusetts • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Oct 9, 2014 · Synced Jul 20, 2026, 7:34 PM EDT
Active, not recruiting Phase 3 Interventional

Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease

NCT05030428
View directory record Official record
Conditions
Atherosclerotic Cardiovascular Disease
Interventions
Inclisiran sodium 300 mg, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years to 100 Years
Enrollment
17,004 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
272
States / cities
Birmingham, Alabama • Fairhope, Alabama • Foley, Alabama + 215 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Jul 20, 2026, 7:34 PM EDT
Completed Phase 2 Interventional Results available

Study of Evinacumab (REGN1500) in Participants With Persistent Hypercholesterolemia

NCT03175367
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Evinacumab, Matching placebo, Background Lipid Modifying Therapy (LMT)
Drug · Other
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
23
States / cities
Los Angeles, California • Newport Beach, California • Boca Raton, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2023 · Synced Jul 20, 2026, 7:34 PM EDT
Completed Phase 4 Interventional Results available

Randomized Trial of Imaging Versus Risk Factor-Based Therapy for Plaque Regression

NCT01212900
View directory record Official record
Conditions
Atherosclerosis, Hypercholesterolemia
Interventions
Statins, HMG CoA
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
50 Years to 99 Years
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 29, 2018 · Synced Jul 20, 2026, 7:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Research Study Looking at New Protein-based Tablets in Healthy Men - Oral Formulation II

NCT05333107
View directory record Official record
Conditions
Healthy Volunteers; High Cholesterol
Interventions
NNC0385-0434 G, NNC0385-0434 F, NNC0385-0434 B
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 64 Years · Male only
Enrollment
152 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
2
States / cities
Cypress, California • Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 11, 2024 · Synced Jul 20, 2026, 7:34 PM EDT
Completed Phase 3 Interventional Results available

Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects Who Are Intolerant to Statins

NCT02135029
View directory record Official record
Conditions
Hyperlipidemia
Interventions
Bococizumab (PF-04950615;RN316), Atorvastatin, Placebo for Bococizumab (PF-04950615;RN316), Placebo for atorvastatin
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
31
States / cities
Denver, Colorado • Bridgeport, Connecticut • Lakeland, Florida + 24 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2017 · Synced Jul 20, 2026, 7:34 PM EDT
Completed Phase 1 Interventional

A Study To Assess The Safety Of PF-05335810 In Hypercholesterolemic Subjects

NCT01720537
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
PF-05335810 Dose A, PF-05335810 Dose B, Placebo, PF-04950615 Dose A, PF-05335810 Dose C, PF-04950615, PF-05335810 Dose D, PF-05335810 Dose E
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
7
States / cities
New Haven, Connecticut • Miami, Florida • South Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2018 · Synced Jul 20, 2026, 7:34 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Inclisiran as Monotherapy in Patients With Primary Hypercholesterolemia Not Receiving Lipid-lowering Therapy.

NCT05763875
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Inclisiran, Ezetimibe, Matching Placebo for Inclisiran, Matching Placebo for Ezetimibe
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
22
States / cities
Birmingham, Alabama • Dothan, Alabama • DeLand, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Jul 20, 2026, 7:34 PM EDT
Completed Phase 3 Interventional Results available

Randomized Clinical Trial Of Bococizumab (PF-04950615; RN316) In Subjects With Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events

NCT01968954
View directory record Official record
Conditions
Hyperlipidemia
Interventions
Bococizumab (PF-04950615;RN316), Placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
711 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
58
States / cities
Birmingham, Alabama • Tucson, Arizona • Encinitas, California + 45 more
Source: ClinicalTrials.gov public record
Updated May 16, 2017 · Synced Jul 20, 2026, 7:34 PM EDT
Completed Phase 2 Interventional Results available

Evaluate Low Doses of AEGR-733 on Hepatic Fat Accumulation by MRS

NCT00559962
View directory record Official record
Conditions
Hyperlipidemia
Interventions
AEGR-733, placebo, AEGR-733 and atorvastatin, AEGR-733 and fenofibrate, AEGR-733 and ezetimibe
Drug
Lead sponsor
Aegerion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
15
States / cities
San Diego, California • Santa Rosa, California • Washington D.C., District of Columbia + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2018 · Synced Jul 20, 2026, 7:34 PM EDT